Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4099664 | 1.00 | OPRL1 (0.47) | OPRL1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL13749435 | 0.85 | HRH3 (0.47) | SLC6A4SLC6A2SLC6A3HRH3KCNH2 | |
| SCHEMBL13750181 | 0.85 | HRH3 (0.47) | SLC6A4SLC6A2SLC6A3HRH3KCNH2 | |
| SCHEMBL4104611 | 0.84 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3HRH3KCNH2 | |
| SCHEMBL4977205 | 0.84 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3HRH3KCNH2 | |
| SCHEMBL4105919 | 0.84 | SLC6A2 (0.45) | SLC6A4SLC6A2SLC6A3HRH3KCNH2 | |
| SCHEMBL4099473 | 0.83 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3HRH3KCNH2 | |
| SCHEMBL4106900 | 0.83 | OPRM1 (0.50) | OPRL1SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL4103236 | 0.83 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3HRH3KCNH2 | |
| SCHEMBL4093737 | 0.81 | CCR3 (0.45) | SLC6A4SLC6A2SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | OPRL1 3352/4885SLC6A4 3834/4885SLC6A2 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.